NanoViricides Inc. (NNVC)

[changes_iv]

Excellent! Your father is healing and that means you and your family are healing with him as well(less and less suffering).

"And by the river upon the bank thereof, on this side and on that side, shall grow all trees for meat (food), whose leaf shall not fade, neither shall the fruit thereof be consumed: it shall bring forth new fruit according to his months, because their waters they issued out of the sanctuary: and the fruit thereof shall be for meat, and the LEAF thereof FOR MEDICINE" (Ezek. 47:12).

I was looking at dosage and the oral regimen of Sovaldi.
http://reference.medscape.com/drug/sovaldi-sofosbuvir-999890

I read nanopatent's post and the U.S. Congress concern for cost $84K. Perhaps the U.S. Congress should help bring a little competition to market from a small company, NanoViricides, Inc. Once the Toxicology and Safety studies are complete, take our small company and low toxicity drugs straight to the Clinical Trials...it will be just a few short months as Doctor Seymour has asserted in the past!

NanoViricides, Inc. Announces Issuance of Fundamental Patents in Australia and the Philippines

In addition, with this technology, the Company has the ability to develop drugs against intractable viral diseases wherein very little virus may be present in circulation. In such cases, the Company can employ the approach of encapsulating multiple antiviral APIs that act by orthogonal mechanisms, and deliver the payload specifically to infected cells by using ligands that bind preferentially to infected cells. Drug combinations are known to often provide enhanced synergistic effectiveness, and have been approved in viral diseases such as HIV/AIDS and Hepatitis C. The encapsulation approach is known to be superior to the simple formulated "fixed drug" combinations approach that is being employed at present. Nevertheless, fixed drug combinations result in the conventional approach of attacking all cells, and are not restricted to attacking infected cells preferentially, and thus are expected to be relatively toxic. Our next generation nanoviricides approach is anticipated to require significant further development and resources. The Company is therefore focusing at present on its wide drug pipeline of six antiviral projects, namely injectable FluCide(TM), oral FluCide(TM), DengueCide(TM), HerpeCide(TM), HIVCide(TM), and the broad-spectrum drug for viral diseases of the external eye.

source: http://online.wsj.com/article/PR-CO-20140324-903241.html